Interestingly, combined treatment with valproate and stiripentol is more effective in Dravet syndrome related to SCN1A mutations compared to mutations in other genes. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.